- Home
- BNTX vs SBAC Comparison
BNTX vs SBAC Comparison
Compare BNTX & SBAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BNTX | SBAC |
|---|---|---|
| Founded | 2008 | 1989 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.8B | 20.2B |
| IPO Year | 2019 | 1999 |
Fundamental Metrics
Financial Performance| Metric | BNTX | SBAC |
|---|---|---|
| Price | $94.73 | $192.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 16 |
| Target Price | $137.40 | ★ $237.50 |
| AVG Volume (30 Days) | ★ 1.6M | 746.8K |
| Earning Date | 11-03-2025 | 11-03-2025 |
| Dividend Yield | N/A | ★ 2.31% |
| EPS Growth | N/A | ★ 25.44 |
| EPS | N/A | ★ 7.95 |
| Revenue | ★ $3,698,814,972.00 | $2,789,256,000.00 |
| Revenue This Year | $2.03 | $7.40 |
| Revenue Next Year | N/A | $1.81 |
| P/E Ratio | ★ N/A | $24.23 |
| Revenue Growth | 3.70 | ★ 4.82 |
| 52 Week Low | $81.20 | $185.13 |
| 52 Week High | $129.27 | $245.16 |
Technical Indicators
Market Signals| Indicator | BNTX | SBAC |
|---|---|---|
| Relative Strength Index (RSI) | 44.49 | 52.18 |
| Support Level | $91.32 | $186.12 |
| Resistance Level | $96.19 | $193.60 |
| Average True Range (ATR) | 2.06 | 3.50 |
| MACD | 0.30 | 0.43 |
| Stochastic Oscillator | 41.78 | 84.08 |
Price Performance
Historical ComparisonAbout BNTX BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
About SBAC SBA Communications Corporation
SBA Communications owns a portfolio of about 45,000 wireless towers throughout North America, South America, and Africa. It leases space on its towers to wireless service providers, who install equipment to support their wireless networks. The company has a very concentrated customer base, with most revenue in each market being generated by the top few mobile carriers. It owns more than 17,000 towers in the US, which account for about 75% of leasing revenue. Internationally, SBA's largest presence is in Brazil, where it owns roughly 10,000 towers. SBA operates as a real estate investment trust.